Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 1/2013

01-01-2013 | Original paper

Prostate cancer incidence and tumor severity in Georgia: descriptive epidemiology, racial disparity, and geographic trends

Authors: Sara E. Wagner, Sarah E. Bauer, A. Rana Bayakly, John E. Vena

Published in: Cancer Causes & Control | Issue 1/2013

Login to get access

Abstract

Purpose

Limited research has been conducted to describe the geographical clustering and distribution of prostate cancer (PrCA) incidence in Georgia (GA). This study describes and compares the temporal and geographic trends of PrCA incidence in GA with a specific focus on racial disparities.

Methods

GA Comprehensive Cancer Registry PrCA incidence data were obtained for 1998–2008. Directly standardized age-adjusted PrCA incidence rates per 100,000 were analyzed by race, stage, grade, and county. County-level hotspots of PrCA incidence were analyzed with the Getis-Ord Gi* statistic in a geographic information system; a census tract-level cluster analysis was performed with a Discrete Poisson model and implemented in SaTScan® software.

Results

Significant (p < 0.05) hotspots of PrCA incidence were observed in nine southwestern counties and six centrally located counties among men of both races. Six significant (p < 0.1) clusters of PrCA incidence rates were detected for men of both races in north and northwest central Georgia. When stratified by race, clusters among white and black men were similar, although centroids were slightly shifted. Most notably, a large (122 km radius) cluster in northwest central Georgia was detected only in whites, and two smaller clusters (0–32 km radii) were detected in Southwest Georgia only in black men. Clusters of high-grade and late-stage tumors were identified primarily in the northern portion of the state among men of both races.

Conclusions

This study revealed a pattern of higher incidence and more advanced disease in northern and northwest central Georgia, highlighting geographic patterns that need more research and investigation of possible environmental determinants.
Literature
1.
2.
3.
McNamara C, Davis V, Bayakly AR, Moon T (2010) Prostate cancer in Georgia, 2002–2006. Georgia Department of Community Health, Division of Public Health, Chronic Disease, Healthy Behaviors, and Injury Epidemiology
4.
Drake BF, Keane TE, Mosley CM, Adams SA, Elder KT, Modayil MV (2006) Prostate cancer disparities in South Carolina: early detection, special programs, and descriptive epidemiology. J S C Med Assoc 102:241–249PubMed
5.
6.
Wagner SE, Hurley DM, Hebert J, McNamara C, Bayakly AR, Vena JE (2012) Cancer mortality-to-incidence ratios in Georgia: describing racial cancer disparities and potential geographic determinants. Cancer 118(16):4032–4045
7.
Steenland K, Goodman M, Liff J, Diiorio C, Butler S, Roberts P, et al (2011) The effect of race and rural residence on prostate cancer treatment choice among men in Georgia. Urology 77(3):581–587
8.
DiIorio C, Steenland K, Goodman M, Butler S, Liff J, Roberts P (2011) Differences in treatment- based beliefs and coping between African American and white men with prostate cancer. J Commun Health 36(4): 505–512
9.
Butler S, Owen-Smith A, DiIorio C, Goodman M, Liff J, Steenland K (2011) Use of complementary and alternative medicine among men with prostate cancer in a rural setting. J Commun Health 36(6):1004–1010
10.
Steenland K, Goodman M, Liff J, Diiorio C, Butler S, Roberts P (2011) Quality of life among men with prostate cancer in rural Georgia. Urology 77(4):927–933
11.
Lefevre ML (1998) Prostate cancer screening: more harm than good? Am Fam Physician 58(2):432–438PubMed
12.
Kulldorff M (1997) A spatial scan statistic. Commun Stat Theory Methods 26:1481–1496CrossRef
13.
Ward E, Jemal A, Cokkinides V, Singh GK, Cardinez C, Ghafoor A et al (2004) Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin 54(2):78–93PubMedCrossRef
14.
Catalona WJ, Smith DS, Ornstein DK (1997) Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277:1452–1455PubMedCrossRef
15.
Dagnelie PC, Schuurman AG, Goldbohm RA, Van den Brandt PA (2004) Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int 93(8):1139–1150PubMedCrossRef
16.
Lambert JD, Yang CS (2003) Mechanisms of cancer prevention by tea constituents. J Nutr 133(10):3262S–3267SPubMed
17.
Nelson WG, DeWeese TL, DeMarzo AM (2002) The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 21:13–16CrossRef
18.
Sinha R, Anderson DE, McDonald SS, Greenwald P (2003) Cancer risk and diet in India. J Postgrad Med 49(3):222–228PubMed
19.
Sommer F, Klotz T, Schmitz-Drager BJ (2004) Lifestyle issues and genitourinary tumours. World J Urol 21(6):402–413PubMedCrossRef
20.
21.
Platz EA, Giovannucci E (2004) The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J Steroid Biochem Mol Biol 92(4):237–253PubMedCrossRef
22.
Soronen P, Laiti M, Torn S, Harkonen P, Patrikainen L, Li Y et al (2004) Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 92(4):281–286PubMedCrossRef
23.
Turesky RJ (2004) The role of genetic polymorphisms in metabolism of carcinogenic heterocyclic aromatic amines. Curr Drug Metab 5(2):169–180PubMedCrossRef
24.
25.
26.
42 Code of Federal Regulations (CFR), Chapter 1, Part 5, Appendix A (October 1, 1993, pp. 34–48) Criteria for designation of areas having shortages of primary medical care professionals [45 FR 76000, Nov. 17, 1980, as amended at 54 FR 8737, Mar. 2, 1989; 57 FR 2480, Jan. 22, 1992]
27.
28.
Hartley D (2004) Rural health disparities, population health, and rural culture. Am J Public Health 94(10):1675–1678
29.
Bynum J, Song Y, Fisher E (2010) Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare. J Am Geriatr Soc 58(4):674–680PubMedCrossRef
30.
Smith RA, Cokkinides V, Brawley OW (2008) Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin 58:161–179PubMedCrossRef
31.
US Preventive Services Task Force (2011) Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 149:185–191
32.
Barry MJ (2009) Screening for prostate cancer—the controversy that refuses to die. N Engl J Med 360:13CrossRef
33.
Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ (2012) Risk- based prostate cancer screening. Eur Urol 61(4):652–661PubMedCrossRef
34.
Greenberg RS, Stevens JA, Whitaker JP (1985) Cancer incidence aong blacks in urban and rural Georgia, 1978–1982. Am J Public Health 75:683–684PubMedCrossRef
35.
Mordukhovich I, Reiter PL, Backes DM, Family L, McCullough LE, O’Brien KM, et al (2011) A review of African American-white differences in risk factors for cancer: prostate cancer. Cancer Causes Control 22(3):341–357
36.
Byers T, Nestle M, McTiernan A, Doyle C, Currie-Williams A, Gansler T et al (2002) American Cancer Society guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 52(2):92–119
37.
Beebe-Dimer JL, Dunn RL, Sarma AV, Montie JE, Cooney KA (2007) Features of the metabolic syndrome and prostate cancer in African-American men. Cancer 109:875–881CrossRef
38.
Hayes RB, Liff JM, Pottern LM, Greenberg RS, Schoenberg JB, Schwartz AG et al (1995) Prostate cancer risk in U.S. blacks and whites with a family history of cancer. Int J Cancer 60(3):361–364PubMedCrossRef
39.
Chang BL, Spangler E, Gallagher S, Haiman CA, Henderson B, Isaacs W, et al (2011) Validation of genome-wide prostate cancer associations in men of African descent. Cancer Epidemiol Biomarkers Prev 20(1):23–32
40.
Allen JD, Kennedy M, Wilson-Glover A, Gilligan TD (2007) African-American men’s perceptions about prostate cancer: implications for designing educational interventions. Soc Sci Med 64(11):2189–2200PubMedCrossRef
41.
Glicksman AS, Meyer A, DiPiero M (2012) Tailored community cancer education programs: pawsox and prostates. J Cancer Educ 25(2):180–183CrossRef
42.
43.
44.
45.
46.
Jemal A, Center MM, DeSantis C, Ward EM (2010) Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19(8):1893–1907
47.
Hsing AW, Tsao L, Devesa SS (2000) International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85(1):60–67PubMedCrossRef
Metadata
Title
Prostate cancer incidence and tumor severity in Georgia: descriptive epidemiology, racial disparity, and geographic trends
Authors
Sara E. Wagner
Sarah E. Bauer
A. Rana Bayakly
John E. Vena
Publication date
01-01-2013
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 1/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-012-0101-0

Other articles of this Issue 1/2013

Cancer Causes & Control 1/2013 Go to the issue

Original paper

The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans

Original paper

Racial variation in vitamin D cord blood concentration in white and black male neonates

Original paper

A multi-ethnic breast cancer case–control study in New Zealand: evidence of differential risk patterns

Original paper

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment

Original paper

Diabetes and risk of pancreatic cancer: a pooled analysis from the pancreatic cancer cohort consortium

Letter to the editor

Formaldehyde and leukemia: missing evidence!
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits